Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Multaq (dronedarone) - Important Safety Information from Sanofi Aventis as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
04/10/2002
Problem Or Issue:
The European Medicines Agency's Committee for Medical Products for Human Use (CHMP) has completed its assessment of the benefits and risks of treatment with Multaq (dronedarone). As a result, the Multaq Summary of Product Characteristics (SmPC) has been modified.
Sanofi Aventis Multaq DHCP Letter 04.10.11.pdf
« Back
Date Printed: 28/03/2024